Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isorhapontigenin is a naturally occurring tetrahydroxylated stilbenoid with a methoxy group, structurally related to resveratrol and an isomer of rhapontigenin. It is found in several plants, including the Chinese herbs Gnetum cleistostachyum and Gnetum parvifolium, as well as the seeds of Aiphanes aculeata. Isorhapontigenin exhibits multiple biological activities such as anti-inflammatory, antineoplastic (anti-cancer), cardioprotective, antiviral, and antioxidant effects[1][2][3]. Mechanistically, it has been shown to induce autophagy and cell death in cancer cells via caspase-dependent pathways; inhibit sphingosine kinases (SPHK1/2), leading to tubulin destabilization; suppress pro-inflammatory cytokines (TNF-α, IL-6, IL-1β); inhibit MAPK/PI3K signaling; regulate cell cycle arrest; modulate Sirt1 activity; protect cardiac microvasculature by inhibiting ferroptosis through PRDX2-MFN2-ACSL4 pathways[4][5][7][8]. Its highest development status for any indication appears to be preclinical research for lung cancer[10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isorhapontigenin.